You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 藥明生物(2269.HK)午間收漲2.68%創新高 獲多家機構看好
格隆匯 06-26 12:02
格隆匯6月26日丨藥明生物(2269.HK)今日盤中高見150.6港元續創上市新高,午間收報149.4港元,漲2.68%,暫成交2.4億港元,最新總市值1945億港元。里昂近日發研報指,參與藥明生物早前舉行的全球投資者日,發現其大部分業務發展都在步入正軌,產能正在提升,目前新型肺炎疫情及中美貿易摩擦未對公司造成太大實際影響。將目標價上調至166.64港元,維持“買入”評級。瑞信亦預計藥明生物分別於明年及2022年可收取譽衡藥業及基石藥業的首筆特許權使用費;另外愛爾蘭疫苗項目料於2022年產生5,000萬至1億美元的可觀收入。維持其跑贏大市評級,目標價上調至159.6港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account